Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
出版年份 2022 全文链接
标题
Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
作者
关键词
-
出版物
Frontiers in Cardiovascular Medicine
Volume 9, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-09-21
DOI
10.3389/fcvm.2022.1010693
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes
- (2022) Judit Hodrea et al. PLoS One
- Cardiovascular Effectiveness of Sodium‐Glucose Cotransporter 2 Inhibitors and Glucagon‐Like Peptide‐1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure
- (2022) Phyo T. Htoo et al. Journal of the American Heart Association
- Effects of SGLT-2 Inhibitors on Vascular Endothelial Function and Arterial Stiffness in Subjects With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- (2022) Ran Wei et al. Frontiers in Endocrinology
- Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry
- (2022) Pasquale Paolisso et al. Cardiovascular Diabetology
- Effects of an SGLT Inhibitor on the Production, Toxicity, and Elimination of Gut-Derived Uremic Toxins: A Call for Additional Evidence
- (2022) Pieter Evenepoel et al. Toxins
- The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study
- (2022) Gabriella di Mauro et al. Pharmaceuticals
- Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease
- (2022) Toshiya Machida et al. Annals of Hepatology
- The Pleiotropic Effects of SGLT2 Inhibitors
- (2021) Lee R. Goldberg JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Hyperglycemia, inflammatory response and infarct size in obstructive acute myocardial infarction and MINOCA
- (2021) Pasquale Paolisso et al. Cardiovascular Diabetology
- Age- and sex-specific risk of urogenital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A population-based self-controlled case-series study
- (2021) Minkyong Kang et al. MATURITAS
- Renoprotection with Sodium‐glucose cotransporter‐2 inhibitors in children:Known and unknown
- (2021) Buchun Jiang et al. NEPHROLOGY
- A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus
- (2021) Junichi Mukai et al. Scientific Reports
- In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia
- (2021) Martina Hüttl et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Current and future therapeutic perspective in chronic heart failure
- (2021) Annamaria Mascolo et al. PHARMACOLOGICAL RESEARCH
- SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies
- (2021) Annamaria Mascolo et al. PHARMACOLOGICAL RESEARCH
- Effects of sodium glucose cotransporter 2 inhibitors on risk of dyslipidemia among patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials
- (2020) Dandan Li et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report
- (2020) Eugene Brailovski et al. ANNALS OF INTERNAL MEDICINE
- Empagliflozin protects heart from inflammation and energy depletion via AMPK activation
- (2020) Chintan N. Koyani et al. PHARMACOLOGICAL RESEARCH
- Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials
- (2020) Adriana Sánchez-García et al. PHARMACOLOGICAL RESEARCH
- Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT ‐1 and ‐2 studies
- (2020) Moshe Phillip et al. DIABETES OBESITY & METABOLISM
- Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
- (2019) Jennifer R Donnan et al. BMJ Open
- Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis
- (2019) Tadashi Toyama et al. DIABETES OBESITY & METABOLISM
- International Consensus on Risk Management of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Treated with Sodium-Glucose Cotransporter (SGLT) Inhibitors
- (2019) Thomas Danne et al. DIABETES CARE
- Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors
- (2019) Susan J. Bersoff-Matcha et al. ANNALS OF INTERNAL MEDICINE
- The future of new drugs for diabetes management
- (2019) Clifford J. Bailey et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial
- (2018) Chantal Mathieu et al. DIABETES CARE
- Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSER
- (2018) Patrick B. Ryan et al. DIABETES OBESITY & METABOLISM
- Comparative risk of genital infections associated with SGLT2 inhibitors: A real-world retrospective cohort study
- (2018) Chintan V. Dave et al. DIABETES OBESITY & METABOLISM
- Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study
- (2018) Paresh Dandona et al. DIABETES CARE
- Impact of empagliflozin in patients with diabetes and heart failure
- (2017) David Pham et al. TRENDS IN CARDIOVASCULAR MEDICINE
- Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
- (2017) Paresh Dandona et al. Lancet Diabetes & Endocrinology
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
- (2016) Nelson B. Watts et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2016) NEW ENGLAND JOURNAL OF MEDICINE
- Fournier's Gangrene: Epidemiology and Outcomes in the General US Population
- (2016) Mathew D. Sorensen et al. UROLOGIA INTERNATIONALIS
- SGLT2 Inhibitors May Predispose to Ketoacidosis
- (2015) Simeon I. Taylor et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
- (2014) Michael Nauck Drug Design Development and Therapy
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started